Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

GHK-Cu iconGHK-Cu3 residuesGHKEach bubble = one amino acid. Size = residue mass. Color = chemical class.

GHK-Cu

Beginner tier: 1 mg, daily · community consensus

Anti-AgingResearch
1 h half-life·Injection/Topical

Also known as: GHK:Cu, copper tripeptide-1, copper peptide GHK

Three amino acids and a copper ion. That's the entire structure of the GHK-Cu peptide, a copper tripeptide the body already produces but loses roughly 60% of by age 60. Pickart and colleagues mapped its gene expression reach to at least 4,000 human genes [1], touching collagen, elastin, inflammation, and antioxidant pathways all at once. No human injectable RCT exists yet. That gap matters. But community experience across 100 to 200+ Reddit threads and biohacker forums consistently describes improved skin texture by week four, faster wound closure, and early hair regrowth at the temples. Available as both injectable and topical, GHK-Cu sits at the intersection of decades-old science and a still-growing user base.

What Is GHK-Cu?

At least 4,000 human genes. That's how many GHK-Cu raises or lowers in gene expression data analyzed by Pickart's group (PMID 26236730 (opens in a new tab))[1]. The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60.

The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in silicosis mice and found lower plasma GHK in silicosis patients [2]. Its research now reaches past skin.

In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5.

The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.

How GHK-Cu Works

GHK-Cu works at the gene expression level. Gene expression data analyzed by Pickart's group show it raises or lowers the activity of at least 4,000 human genes, suppressing some destructive pathways, when human cells are exposed to the peptide [1]. That's not a vague claim; the gene list is published and includes collagen I, III, and V, elastin, decorin (the scaffolding protein collagen needs to organize correctly), and antioxidant-related genes (Pickart and colleagues, Cosmetics 2015).

The copper(II) ion is load-bearing. Without it, the tripeptide GHK has limited biological activity. Copper activates lysyl oxidase, an enzyme required for collagen and elastin crosslinking. It also supports superoxide dismutase activity, which ties into the antioxidant gene data.

At the tissue level, GHK-Cu attracts both immune cells and endothelial cells to wound sites. This dual recruitment accelerates debris clearance and new blood vessel formation (angiogenesis). Pickart and Margolina described this in a 2008 review [4] as a "reset" toward a younger tissue repair program.

Recent work has extended these findings. Bian and colleagues showed GHK-Cu binds PRDX6 and eases lung fibrosis in silicosis mice (Redox Biology, 2024)[2]. A 2025 mouse study found it eased DSS-induced colitis, with SIRT1/STAT3 signaling implicated [5]. The peptide's reach keeps expanding, but the core mechanism remains the same: copper-dependent gene modulation that shifts tissue toward repair.

GHK-Cu Benefits

  • GHK-Cu benefits center on collagen production, skin rejuvenation, and wound healing.
  • Collagen I, III, and V synthesis all increase in fibroblast cultures exposed to GHK-Cu, confirmed by Maquart and colleagues in the original 1988 study [6]. That's the structural backbone of firmer, younger-looking skin.
  • Community users consistently report visible fine line reduction and improved skin texture by weeks four to six. Over 100 Reddit threads in r/Peptides describe this as the single most reproducible outcome.
  • Wound healing acceleration is both the oldest and best-supported benefit. Small cuts, post-surgical incisions, and acne scarring heal faster in both topical trials (n = 41 to 71) and community reports.
  • Hair shedding decreases within four to six weeks for some users, with early regrowth at the temples or crown reported by week eight to sixteen. Published evidence is limited to follicle-level in vitro data, but user consistency is high.
  • GHK-Cu's antioxidant effects come from lab and animal studies so far. Pickart's 2012 review [3] describes that antioxidant action and the peptide's high affinity for copper ions. A 2015 follow-up from the same group in Cosmetics proposes changes in antioxidant-related genes as the reason.
  • Newer research points to anti-fibrotic potential beyond skin. In the 2024 silicosis study [2], GHK-Cu protected mouse lung tissue by binding PRDX6; patients with silicosis also had lower plasma GHK than controls.

GHK-Cu: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 16 key studies·Research only

Preclinical evidence is strong for collagen stimulation, wound healing, and gene expression modulation (at least 4,000 human genes, up or down).

Dosing studied: Topical: 1–3% concentration. Injectable (community): 0.5–3 mg/day SubQ. No clinical trial establishes an injectable dose range for humans.
Read the evidence (key study, limitations)

Human clinical data is limited to small topical cosmetic trials. No human RCTs for injectable route exist. 2024–2025 mouse studies expanded applications to pulmonary protection [2] and colitis [5]. Core collagen and elastin mechanisms are well-validated in vitro and in animal models.

Key Study

Pickart et al.: multiple landmark studies on GHK-Cu gene expression modulation (PMID 29986520, 26236730). Most recent: PMID 38879894 (Bian Y et al., Redox Biology, Sep 2024): GHK-Cu attenuates lung fibrosis in silicosis mice via PRDX6; includes plasma GHK data from 15 patients and 11 controls.

Limitations

No human RCTs for injectable route. Topical clinical trials are small (n=41–71), non-blinded, or lack placebo arms. Nearly all mechanistic data is in vitro or murine. Skin penetration of topical GHK-Cu is limited due to hydrophilicity: liposomal delivery unmeasured (PMID 39795193). Pro-angiogenic activity raises theoretical oncology concern (NCI) that is unresolved in humans.

Community Experience
Strong
4.2/5
Based on ~100–200+ Reddit threads (r/Peptides, r/Biohackers)

Highly positive community reception.

Community dosing: 1–2 mg/day SubQ for injectable; 1–3% topical. Most users start at 0.5–1 mg/day and titrate up.
Read the reports (what users report 5, common issues 5)

Consistently rated one of the most tolerated anti-aging peptides. Skin texture improvement at 4–6 weeks is the most reproducible reported outcome. Hair regrowth and wound healing are common secondary uses. Topical overuse ("copper uglies") is the most-discussed adverse pattern.

What users report (5)
  • Improved skin texture and fine line reduction by weeks 4–6
  • Accelerated wound, scar, and post-procedure healing
  • Reduced hair shedding and early regrowth at temples/crown (8–16+ week timeline)
  • Enhanced results after microneedling when applied immediately post-session (topical)
  • General skin firmness and elasticity improvement
Common issues (5)
  • "Copper uglies": paradoxical skin degradation from topical overuse or aggressive post-microneedling application (MMP-1 upregulation outpaces collagen synthesis)
  • Injection site burning/stinging from copper ions: #1 injectable complaint
  • mcg vs mg dosing confusion: common 1,000× calculation error in beginners
  • Short reconstituted stability (~2–3 weeks) limits batch prep
  • Zinc supplementation >50 mg/day competes with copper transport, reducing efficacy
Partially Aligned

Science and community agree on core benefits (collagen, wound healing, skin rejuvenation) and the topical route. Divergence exists on injectable dosing: community doses 1–3 mg/day SubQ without a published human dose-finding trial to support any specific number. Community primarily uses injectable for systemic anti-aging while published research focuses on topical and localized wound healing. Pro-angiogenic concern is under-discussed in community protocols.

GHK-Cu Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner1 mg
DailyTrack
Moderate2 mg
DailyTrack
Aggressive3 mg
DailyTrack
Note:

The blue-green color when you reconstitute is not contamination. It's the copper(II) ion doing exactly what it should. If your solution is colorless after proper reconstitution, that's actually the problem: copper may have dissociated, and potency drops with it.

Reconstitution math for common vial sizes: a 5 mg vial plus 2 mL bacteriostatic water gives you 2,500 mcg/mL. A 1 mg dose (1,000 mcg) equals 0.4 mL, which is 40 units on a U-100 insulin syringe. For the 50 mg vial plus 5 mL bacteriostatic water, you get 10,000 mcg/mL; a 1 mg dose is just 0.1 mL or 10 units.

Store reconstituted vials in a dark refrigerator. Copper ions are photosensitive. Expect two to three weeks of usable shelf life.

Start at 500 mcg/day for injectable and titrate up over two weeks. Evening injection is the community standard. Rotate abdominal sites and don't hit the same spot more than once per week; lipodystrophy from poor rotation is a real and visible consequence.

Cycling Protocol

On Period
8 weeks
Off Period
4 weeks

Cycle 4-8 weeks for injectable use. Topical application can be used continuously without cycling.

Calculate your GHK-Cu dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

GHK-Cu Protocols by Goal

beginnerCommunity12 weeks minimum; can continue indefinitely
Foundation
Wk 1–4
1% GHK-Cu topical · Once daily (PM) · Topical
Maintenance
Wk 5–12
2% GHK-Cu topical · Once or twice daily · Topical

Expected: Improved skin texture and hydration by weeks 2–4. Visible fine line reduction and improved firmness by weeks 6–8. Collagen remodeling continues through week 12.

Monitor: Discontinue if paradoxical skin worsening occurs (copper uglies: accelerated sagging or wrinkling). This indicates MMP-1 overactivation; reduce concentration and frequency.

How to Use GHK-Cu

  1. 1
    Step 1

    Gather supplies: GHK-Cu lyophilized vial, bacteriostatic water, alcohol swabs, U-100 insulin syringe (29 to 31 gauge, 0.5 inch needle).

  2. 2
    Step 2

    Clean both vial stoppers with alcohol swabs and let dry.

  3. 3
    Draw your bacteriostatic water volume

    For a 5 mg vial, use 2 mL. For a 50 mg vial, use 5 mL.

  4. 4
    Inject the water slowly against the vial wall

    Do not spray directly onto the powder. Swirl gently until dissolved. The solution will turn blue-green; this is normal and expected.

  5. 5
    Calculate your dose

    At 5 mg in 2 mL: 1 mg (1,000 mcg) = 40 units on the syringe. At 50 mg in 5 mL: 1 mg = 10 units on the syringe.

  6. 6
    Step 6

    Draw your dose, removing air bubbles by tapping the syringe barrel.

  7. 7
    Step 7

    Pinch a fold of abdominal skin (or near your target area for localized effects). Insert needle at a 45-degree angle. Inject slowly.

  8. 8
    Step 8

    Withdraw the needle, apply light pressure with an alcohol swab. If you experience copper sting, hold a cold compress for 60 seconds.

  9. 9
    Rotate injection sites

    Map at least six to eight abdominal locations and cycle through them. No site more than once per week.

  10. 10
    Step 10

    Store the reconstituted vial upright in a dark refrigerator (2 to 8 degrees Celsius). Use within two to three weeks.

Alternative Routes

Subcutaneous injection

Standard systemic: 0.5–2 mg/day. Peri-target SubQ (near scalp for hair, face perimeter for skin) uses same dose with smaller volume and finer needle (31G).

Estimated SC bioavailability ~90–95%. Rapid plasma clearance (~1 hour half-life) but cellular effects persist. Evening injection preferred. No more than 1 injection per site per week to prevent lipodystrophy.

Topical (cream, serum, gel)

1–3% concentration standard; up to 5% in clinical formulations. Skin penetration is limited by hydrophilicity: microneedling or liposomal encapsulation significantly enhances delivery.

No meaningful systemic copper load at standard concentrations. "Copper uglies" risk at high concentrations or aggressive post-microneedling use. MMP-1 upregulation may outpace collagen synthesis. Can be used continuously (no cycling required) at ≤3% concentration.

Microneedling-assisted topical

Apply 0.5–2% GHK-Cu serum immediately post-microneedling (0.5–1 mm needle depth). Wait 48–72 hours minimum in beginners to assess copper irritation response on disrupted skin barrier.

Do not exceed 2% concentration immediately post-microneedling. Disrupted skin barrier allows excess copper penetration and amplifies MMP-1 upregulation risk. Space microneedling sessions 3–4 weeks apart.

Mixing your own vial? Use the GHK-Cu reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

GHK-Cu Stacking Protocols

Works With

Avoid

Zinc supplements >50 mg/day

Competitive inhibition at copper transport sites. High-dose zinc displaces copper in transporter binding, reducing GHK-Cu cellular uptake and bioavailability.

Copper-chelating agents (penicillamine, trientine)

Directly chelate the copper ion in GHK-Cu, reducing bioavailability by 60–80% and unpredictably altering free copper levels. Critical drug interaction.

Do not combine
High-dose topical ascorbic acid (≥15%) applied concurrently

High-concentration ascorbic acid chelates copper ions, reducing topical GHK-Cu activity. Separate topical application by at least 2 hours.

How much does GHK-Cu cost?

Typical price

$0.452 to $0.70 per mg

Typical $0.55

Middle half of 114 US prices for 100 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
Compounding pharmacy (Rx required): topical clinical-grade cream ~$80–$150/bottle. Injectable GHK-Cu has no compounding pharmacy access today, so no compounded injectable price applies. It is listed as withdrawn from FDA Category 2 (FDA page current as of April 22, 2026) and is not on the 503A bulks list; non-injectable GHK-Cu is back on FDA's 503A Category 1 list as of May 14, 2026.

Pricing updated 2026-04-09

GHK-Cu Side Effects

The most serious concern with GHK-Cu is its pro-angiogenic activity. The NCI flagged this years ago: a peptide that promotes new blood vessel formation could, in theory, support tumor vascularization. No human case has confirmed this, but no study has ruled it out either. Anyone with an active malignancy should not use GHK-Cu without oncologist clearance.

Copper toxicity is the second concern worth taking seriously. Continuous long-term use without lab monitoring creates an accumulation risk. Wilson's disease, hemochromatosis, and any copper metabolism disorder are absolute contraindications. Symptoms of copper excess include nausea, metallic taste, and jaundice; if these appear, stop immediately and get serum copper checked.

Published side effects in topical trials are mild. Skin irritation, redness, and occasional contact sensitivity at higher concentrations. The more interesting adverse pattern comes from the community: "copper uglies." This is paradoxical skin worsening (sagging, accelerated wrinkling) caused by MMP-1 matrix metalloproteinase upregulation outpacing collagen synthesis. It happens most often with topical overuse or aggressive post-microneedling application. The fix is simple: drop to 1% concentration and wait 48 to 72 hours after microneedling before applying.

Injectable side effects are dominated by injection site reactions. Burning and stinging from the copper ions is the number one complaint in community threads. Diluting with more bacteriostatic water, using a 31-gauge needle, and applying a cold compress for 60 seconds post-injection helps. Site rotation matters; no location should get more than one injection per week. Poor rotation leads to lipodystrophy (localized fat atrophy), which is harder to reverse than it sounds.

At doses above 1.5 mg/day, some users report nausea and metallic taste. These are dose-dependent and resolve with reduction.

Reconstituted stability is limited to two to three weeks refrigerated. Potency drops 15 to 30% by week four according to community tracking. The mcg versus mg calculation error is a real hazard for beginners; GHK-Cu vials are labeled in mg but doses are discussed in mcg. 1 mg equals 1,000 mcg. Getting this wrong by a factor of 1,000 is not theoretical; it's the most common beginner mistake in the community.

Contraindications: Wilson's disease or copper metabolism disorders. Known hypersensitivity to GHK-Cu or copper compounds. Pregnancy or breastfeeding (no safety data). Hemochromatosis. Active malignancy without oncologist clearance. Severe kidney or liver dysfunction.

Drug interactions: copper-chelating agents (penicillamine, trientine) reduce bioavailability by 60 to 80%. Zinc above 50 mg/day competes at copper transport sites. High-concentration topical vitamin C (15%+) chelates copper; separate application by two or more hours. Immunosuppressants may interact with the healing response; consult a prescriber.

Common Issues & Solutions

Blue-green solution is NORMAL: intact copper(II)-peptide complex. A colorless solution may indicate copper dissociation and reduced potency. Do not discard blue-green vials.

Injection site burning/copper sting: reduce dose by 50% and dilute with more BAC water; use 31G needle; apply cold compress 60 seconds post-injection. Persistent site reactions indicate inadequate rotation (no site should receive >1 injection/week).

mcg/mg calculation error: GHK-Cu research vials are labeled in mg (5 mg, 50 mg); doses are discussed in mcg. 1 mg = 1,000 mcg. At 5mg vial + 2mL BAC water = 2,500 mcg/mL; a 1 mg dose = 0.4 mL = 40 IU on U100 syringe. Verify concentration calculation before every new vial.

"Copper uglies" from topical overuse: paradoxical skin worsening (sagging, wrinkling) caused by MMP-1 upregulation outpacing collagen synthesis at high concentrations or immediately post-microneedling. Fix: reduce to 1% concentration, wait 48–72 hours after microneedling before applying, space to once daily.

No response by week 6 (injectable): confirm proper SubQ depth (not intradermal: intradermal causes welts and poor absorption), verify reconstituted concentration, and rule out zinc supplement competition (>50 mg/day zinc blocks copper transport).

Ask AI about this page

Ask AI for a second opinion on GHK-Cu dosing and side effects

Contraindications

  • Wilson's disease or other copper metabolism disorders
  • Known hypersensitivity to GHK-Cu or copper compounds
  • Pregnancy or breastfeeding (insufficient safety data)
  • Hemochromatosis or copper overload conditions
  • Active malignancy without oncologist clearance (GHK-Cu modulates growth-related genes)
  • Severe kidney or liver dysfunction (may impair peptide clearance)

Drug Interactions

  • Copper-chelating agents (penicillamine, trientine): may reduce GHK-Cu bioavailability by 60-80% and alter free copper levels
  • Zinc supplements above 50mg/day: competitive inhibition at copper transport sites can reduce cellular uptake
  • Topical vitamin C serums (high-concentration ascorbic acid): may chelate copper and reduce activity; separate application by 2+ hours
  • Immunosuppressants: GHK-Cu may amplify healing responses; consult prescriber before combining
  • Directly chelate the copper ion in GHK-Cu, reducing bioavailability by 60–80% and unpredictably altering free copper levels. Critical drug interaction.

Product Quality

Recommended Monitoring

TestWhenTarget
Serum copperBaseline; recheck at 8 weeks if running extended or high-dose injectable cycles (>1.5 mg/day)70–140 mcg/dL (adult normal)
CeruloplasminBaseline if Wilson's disease or copper metabolism disorder is suspected15–60 mg/dL
Liver function panel (ALT, AST, bilirubin)Baseline for advanced protocols; 8-week check if running high-dose or extended cyclesALT <56 U/L, AST <40 U/L (lab-specific ranges apply)
Serum zincBaseline if taking zinc supplements at >25 mg/day60–120 mcg/dL
Serum copper

Injectable GHK-Cu adds systemic copper load; monitoring confirms copper remains within normal range and accumulation has not occurred

Ceruloplasmin

Ceruloplasmin is the primary copper transport protein; low ceruloplasmin indicates impaired copper handling and is a contraindication to GHK-Cu use

Liver function panel (ALT, AST, bilirubin)

Copper accumulation is hepatotoxic at excess levels; liver enzymes provide early warning. Also relevant given GHK-Cu modulation of hepatic gene expression.

Serum zinc

High-dose zinc (>50 mg/day) competitively inhibits copper transport and reduces GHK-Cu efficacy; adjust zinc supplementation if low response is observed

GHK-Cu Before and After

Weeks 1-2

Initial cellular signaling begins. Gene expression shifts toward repair pathways. Skin may feel slightly more hydrated. No visible changes yet.

Weeks 2-4

Early improvements in skin texture and tone. Minor wounds and blemishes heal faster. Collagen synthesis is ramping up at the cellular level.

Weeks 4-6

Noticeable reduction in fine lines. Skin appears firmer and more elastic. Hair shedding may decrease in those using for hair regrowth.

Weeks 6-8

Peak results for an 8-week injectable cycle. Visible improvement in wrinkles, skin firmness, and wound healing. Some users report early hair regrowth at the temples or crown.

Post-cycle
4-week off period

Benefits persist due to sustained collagen remodeling. Topical GHK-Cu can be continued during the off period to maintain skin-level results.

What to Expect

Weeks 1 to 2 (Cellular Signaling Onset): Gene expression changes begin within hours. Repair genes, collagen I/III/V, and elastin pathways activate at the cellular level. Nothing visible yet. Most users notice their skin feels slightly more hydrated, and small injection-site nicks heal faster than expected. The blue-green solution color surprises first-timers, but it confirms the copper-peptide complex is intact. Expect injection site burning from the copper ions; mild redness is common. Nausea at doses above 1.5 mg is rare.

Weeks 2 to 4 (Early Tissue Response): Collagen synthesis is ramping up. Elastin deposition is underway. Hair follicle miniaturization signals may start to reverse. Community users describe an improved skin "glow" and noticeably faster healing of minor wounds and blemishes. Topical users report more even skin tone. Hair shedding may slow down. Injection site reactions typically normalize by this point if you're rotating properly. Some users report occasional metallic taste at higher doses.

Weeks 4 to 6 (Visible Skin Changes): This is the most consistent benefit window in community reports. Skin feels firmer. Fine lines are visibly reduced. Texture is smoother. Some users see early hair regrowth at the temples or crown. Topical trial data supports measurable increases in skin density and elasticity during this timeframe.

Weeks 6 to 8 (Peak Cycle Results): Maximum collagen remodeling within the cycle. Anti-fibrotic effects peak. Gene expression changes are fully established. Wrinkle reduction and skin firmness hit their best. Stacked users running the GLOW blend (BPC-157 and TB-500) report more dramatic results. Watch for lipodystrophy if you've been lazy with site rotation.

Post-cycle, 4-week off (Consolidation): Collagen remodeling is slow by nature. Benefits persist four to eight weeks after stopping because the ECM changes are structural, not pharmacological. Most users maintain visible improvements through the entire off period. Topical GHK-Cu at 2% or lower is commonly continued during the break for skin maintenance.

Detailed Timeline: Science vs Community

Weeks 1–2
Science

Gene expression modulation begins within hours of administration. Upregulation of repair genes, collagen I/III/V, and elastin synthesis initiated at the cellular level. No macroscopic changes expected.

Community

Skin feels slightly more hydrated. Some users notice injection site heals faster than usual. No visible skin changes yet. Blue-green solution color often surprises first-time users (it is normal).

Weeks 2–4
Science

Collagen synthesis ramping up. Elastin deposition beginning. Wound healing acceleration measurable histologically. Hair follicle miniaturization signals may begin to reverse.

Community

Improved skin texture and "glow." Minor wounds and blemishes heal noticeably faster. Topical users report better skin tone evenness. Hair shedding may decrease.

Weeks 4–6
Science

Measurable increases in skin density and elasticity based on topical trial data. Fine line reduction becomes histologically measurable.

Community

Most consistent benefit window: skin firmer, fine lines reduced, texture smoother. First reports of early hair regrowth appearing at temples or crown.

Weeks 6–8
Science

Maximum collagen remodeling within the cycle. Anti-fibrotic effects peak. Gene expression changes fully established.

Community

Visible wrinkle reduction and skin firmness peak. Wound/scar remodeling visibly improved. Stacked users (GLOW blend with BPC-157/TB-500) report more dramatic outcomes.

Post-cycle (4-week off)
Science

Collagen remodeling is slow: benefits persist 4–8 weeks post-cycle due to sustained ECM changes. Gene expression returns toward baseline gradually.

Community

Most users maintain visible improvements through the off period. Topical GHK-Cu commonly continued during off cycle for skin maintenance at ≤2% concentration.

Pharmacokinetics

Half-Life
45min
Bioavailability
SC: estimated 90-95%; Topical: limited to local tissue
Tmax
~30 minutes (SC injection)
Data Confidence
low

Source: Estimated from plasma degradation studies; rapid enzymatic cleavage by peptidases gives a ~30-60 min range

Pharmacokinetics: Active Dose Over Time

t½ = ~1 hour

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
3
Molecular Weight
403.92 Da
Formula
C14H24CuN6O4
Type
Small Molecule
Sequence
GHK
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider GHK-Cu

  • Adults seeking to reduce visible signs of skin aging (fine lines, wrinkles, loss of elasticity)
  • Individuals recovering from wounds, surgical incisions, or skin injuries
  • Men and women experiencing age-related hair thinning
  • Adults over 40 with declining endogenous GHK levels
  • Patients looking for collagen and elastin support without growth hormone use

Related Peptides

What Changed for GHK-Cu

  1. Safety

    Corrected Oct 20, 2026: GHK-Cu side effects drop an unsourced line that injected copper stays below toxic levels; the copper limit is for intake, per IOM 2001.

    Before: At typical community doses (1 to 2 mg/day subcutaneous), the copper load stays well below toxic thresholds. After: Line dropped: no upper limit is set for injected copper (the IOM limit covers intake from food, water and supplements); the accumulation caution and copper checks stay.

    What this does not mean: No new copper risk was found, and the dose tiers are unchanged. The IOM set its 10 mg a day upper limit for copper from food, water and supplements. It gives no figure for injected copper.

    Source: Institute of Medicine 2001, Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc, chapter 7 (Copper): adult upper limit 10,000 mcg/day, set on liver damage (PMID 25057538) (opens in a new tab) · Archived snapshot (opens in a new tab)

  2. Dosing

    Corrected Oct 19, 2026: GHK-Cu's moderate tier is 2 mg daily, not 2.5 mg, the top of its 1 to 2 mg community range; no trial set an injected dose, per PubMed.

    Before: Beginner 1,000, moderate 2,500, aggressive 3,000 mcg daily After: Beginner 1,000, moderate 2,000, aggressive 3,000 mcg daily

    What this does not mean: No new study, and no dose is newly supported: the tiers are community figures. GHK-Cu's human trials are topical, such as Miller 2006; no human study has tested it alone as an injection. Beginner 1 mg and aggressive 3 mg are unchanged.

    Source: Arch Facial Plast Surg 2006, Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (Miller et al.), a randomized trial of topical GHK-Cu (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  3. Safety

    Corrected Oct 17, 2026: GHK-Cu's safety grade is now B, not A; FDA says human data on injectable GHK-Cu are limited, per its Category 2 page.

    Before: A After: B

    What this does not mean: No new safety finding, and the doses did not change. Grade A needs extensive human data or long-established use. The human data for GHK-Cu are small topical skin studies; no human study has tested it as an injection.

    Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy

  4. Regulatory

    FDA put non-injectable GHK-Cu back in 503A category 1 after a nominator kept that route, per the FDA 503A categories list updated May 14, 2026.

    What this does not mean: Category 1 means under evaluation. It is not the 503A bulks list, and injectable GHK-Cu stays out of every category.

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) (opens in a new tab) · Saved copy

  5. Regulatory

    FDA took non-injectable GHK-Cu off 503A category 1 on Apr 22, 2026 after its nominations were withdrawn, per the FDA 503A categories list.

    What this does not mean: It concerns 503A compounding nominations only. It is not a new FDA safety finding about GHK-Cu.

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) (opens in a new tab) · Saved copy

  6. RegulatoryEffective

    Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.

    What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).

    Also covers: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, LL-37, Dihexa, PEG-MGF, Melanotan II

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Dates to watch

  1. Committee review

    FDA intends to consult its compounding advisory committee on adding these peptides to the 503A bulks list, per FDA.

    What this does not mean: No meeting date is set yet. A committee vote is advice to FDA, not a rule; the 503A bulks list changes only through notice-and-comment rulemaking.

    Also covers: LL-37, Dihexa, Melanotan II, PEG-MGF

Peptide Schedule Research TeamReviewed Aug 7, 202616 Citations

References

  1. [1]Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]The glycyl-L-histidyl-L-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6 (Redox Biology 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health (Pickart et al., Oxid Med Cell Longev 2012) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]The human tri-peptide GHK and tissue remodeling (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms (Front Pharmacol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu2+ (opens in a new tab)PubMed (opens in a new tab)PubMed

Additional References

Related Resources

Related Tools

Further Reading

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C
After Reconstitution
Refrigerate, use within 3-4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

Yes, that blue-green color is actually a good sign. It means the copper-peptide complex is intact. A colorless solution could actually indicate copper dissociation, which would mean reduced potency. The color comes from the copper(II) ion coordinated to the peptide.

Perilesional injections near the target area are used clinically for wound healing and sometimes near the scalp for hair regrowth. But copper irritation is more pronounced at highly vascularized or thin-skinned sites. Most protocols use abdominal SC for systemic effects. Peri-target injection adds localized benefit but expect more site reactions.

Community consensus is 2-3 weeks refrigerated if you used sterile reconstitution technique. Some users report 15-30% potency loss by week 4. Keep it protected from light and don't freeze it.

Depends on the route. Topical formulations can be used continuously since the systemic copper load is minimal. Injectable should be cycled; 8 weeks on, 4 weeks off; to avoid potential copper accumulation and maintain receptor sensitivity.

No documented pharmacokinetic interaction. GHK-Cu raises or lowers the expression of at least 4,000 human genes, and some community discussions on ExcelMale explore whether that overlaps with androgen pathways. But it's theoretical. No clinical data supports adjusting either compound when using both.